Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
62 hedge funds and large institutions have $38.3M invested in Zynerba Pharmaceuticals, Inc in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 18 reducing their positions, and 8 closing their positions.
68% more call options, than puts
Call options by funds: $875K | Put options by funds: $521K
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
7% more funds holding
Funds holding: 58 → 62 (+4)
11% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 18
33% less capital invested
Capital invested by funds: $57.1M → $38.3M (-$18.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$877K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$872K |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$451K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$197K |
| 5 |
AGM
Alpine Global Management
New York
|
+$160K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.64M |
| 2 |
D.E. Shaw & Co
New York
|
-$920K |
| 3 |
Two Sigma Investments
New York
|
-$608K |
| 4 |
Two Sigma Advisers
New York
|
-$251K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$185K |
ZYNE Hedge Fund Activity: Q4 2021 in Review
62 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q4 2021, worth a combined $38.3M — down 33% from $57.1M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ZYNE positions and 8 closed out — a net gain of 4 holders — while 16 added to existing stakes and 18 trimmed.
The largest buyer was GSA Capital Partners, adding an estimated $877K. The largest seller was Millennium Management, exiting entirely with an estimated $1.64M sold.
- 62 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q4 2021, up from 58 in Q3 2021.
- Funds reported $38.3M of Zynerba Pharmaceuticals, Inc stock for Q4 2021, down 33% quarter-over-quarter.
- 12 funds opened new Zynerba Pharmaceuticals, Inc positions in Q4 2021 and 8 closed out, a net change of +4 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q4 2021 was GSA Capital Partners, an estimated $877K added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q4 2021 was Millennium Management, an estimated $1.64M sold.
Based on aggregated 13F filings for Q4 2021.